Notably, these findings could avail new mechanistic insights into the role of cholesterol in the Hippo/YAP pathway, uncover the basis of intrinsic resistance to SOAT1-targeted therapy, and suggest a novel approach for cholesterol metabolic-targeted treatment of colon cancers. The gene discussed is SOAT1; the disease is malignant colon neoplasm.